Table 3.
Estimates of the SMD as summary measure for the difference in [18F]FDG (SUVmax) uptake between clinical subtypes according to a simplified classification
| Comparisons | Studies | Patients | Meta-analysis | Subgroup | Egger | ||||
|---|---|---|---|---|---|---|---|---|---|
| No | I2 (%) | SMD | 95% CI | P | P | ||||
| Primary analyses | |||||||||
| ER+/HER2− versus HER2+ | 5 | 755 | 302 | 0.0 | − 0.34 | − 0.53, − 0.16 | 0.0070 | – | 0.2633 |
| ER+/HER2− versus TNBC | 6 | 814 | 309 | 56.1 | − 0.89 | − 1.20, − 0.58 | 0.0008 | – | 0.0247 |
| HER2+ versus TNBC | 5 | 302 | 291 | 64.7 | − 0.54 | − 0.93, − 0.14 | 0.0193 | – | 0.3140 |
| Sensitivity analyses | |||||||||
| ER+/HER2− versus HER2+ | 8 | 1153 | 416 | 30.9 | − 0.38 | − 0.56, − 0.20 | 0.0016 | 0.3985 | 0.7816 |
| ER+/HER2− versus TNBC | 9 | 1212 | 424 | 43.0 | − 0.91 | − 1.10, − 0.73 | < 0.0001 | 0.3252 | 0.0246 |
| HER2+ versus TNBC | 8 | 416 | 406 | 22.9 | − 0.50 | − 0.76, − 0.24 | 0.0025 | 0.6884 | 0.5186 |
Data derived from the primary and sensitivity analyses are presented
CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; SMD, standardized mean difference; TNBC, triple negative breast cancer